Case presentation and management of Lyme disease patients: a 9-year retrospective analysis in France

Introduction Lyme borreliosis (LB) is the most common vector disease in temperate countries of the northern hemisphere. It is caused by Borrelia burgdorferi sensu lato complex. Methods To study the case presentation of LB in France, we contacted about 700 physicians every year between 2003 and 2011. An anonymous questionnaire was established allowing the collection of 3,509 cases. The information collected was imported or directly entered into databases and allowed identifying variables that were validated in a multiple correspondence analysis (MCA). Results Sixty percent of the cases were confirmed, 10% were probable, 13.5% doubtful, 10.2% asymptomatic seropositive and 6.3% were negative. The clinical manifestations reported were cutaneous (63%), neurological (26%), articular (7%), ocular (1.9%) and cardiac (1.3%). Almost all patients were treated. When focusing more particularly on confirmed cases, our studies confirm that children have a distinct clinical presentation from adults. There is a gender effect on clinical presentation, with females presenting more often with erythema migrans or acrodermatitis chronica atrophicans than males, while males present more often with neurological signs or arthritis than females. Discussion This is the first time that a comprehensive study of suspected Lyme borreliosis cases has been conducted over several years in France. Although we were not able to follow the clinical course of patients after treatment, these results suggest the interest of refining the questionnaire and of following up a cohort of patients over a sufficiently long period to obtain more information on their fate according to different parameters.

[1]  S. Bonin,et al.  The Impact of Telemedicine in the Diagnosis of Erythema Migrans during the COVID Pandemic: A Comparison with In-Person Diagnosis in the Pre-COVID Era , 2022, Pathogens.

[2]  D. Brisson,et al.  Borrelia burgdorferi strain and host sex influence pathogen prevalence and abundance in the tissues of a laboratory rodent host , 2022, Molecular ecology.

[3]  K. Baldwin,et al.  Early Disseminated Lyme Disease: Cranial Neuropathy, Meningitis, and Polyradiculopathy. , 2022, Infectious disease clinics of North America.

[4]  M. Venetikou,et al.  Climate Changes Exacerbate the Spread of Ixodes ricinus and the Occurrence of Lyme Borreliosis and Tick-Borne Encephalitis in Europe—How Climate Models Are Used as a Risk Assessment Approach for Tick-Borne Diseases , 2022, International journal of environmental research and public health.

[5]  Ana M Ortega-Villa,et al.  Characteristics and outcome of facial nerve palsy from Lyme neuroborreliosis in the United States , 2022, Annals of clinical and translational neurology.

[6]  Y. Chaix,et al.  Lyme neuroborreliosis in pediatrics: A retrospective, descriptive study in southwest France. , 2021, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[7]  F. Strle,et al.  Comparison of Lyme Disease in the United States and Europe , 2021, Emerging infectious diseases.

[8]  D. Raoult,et al.  Sexual Dimorphism and Gender in Infectious Diseases , 2021, Frontiers in Immunology.

[9]  J. Paprocka,et al.  Lyme Neuroborreliosis in Children , 2021, Brain sciences.

[10]  R. Métras,et al.  Exploratory Space–Time Analyses of Reported Lyme Borreliosis Cases in France, 2016–2019 , 2021, Pathogens.

[11]  P. Godoy,et al.  Use of Multiple Correspondence Analysis and K-means to Explore Associations Between Risk Factors and Likelihood of Colorectal Cancer: Cross-sectional Study , 2021, Journal of medical Internet research.

[12]  J. Langley,et al.  Lyme disease in children: Data from the Canadian Paediatric Surveillance Program. , 2019, Ticks and tick-borne diseases.

[13]  G. Lina,et al.  Lyme borreliosis and other tick-borne diseases. Guidelines from the French Scientific Societies (I): prevention, epidemiology, diagnosis. , 2019, Medecine et maladies infectieuses.

[14]  V. Laugel,et al.  Lyme neuroborreliosis in children: Report of nine cases and a review of the literature. , 2019, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[15]  H. Wilking,et al.  Incidence of notified Lyme borreliosis in Germany, 2013–2017 , 2018, Scientific Reports.

[16]  B. H. Skogman,et al.  Occurrence of erythema migrans in children with Lyme neuroborreliosis and the association with clinical characteristics and outcome – a prospective cohort study , 2018, BMC Pediatrics.

[17]  F. Strle,et al.  Lyme borreliosis-from tick bite to diagnosis and treatment. , 2018, FEMS microbiology reviews.

[18]  G. Rouleau,et al.  Clinical presentation of Lyme disease in the higher-risk region of Quebec: a retrospective descriptive study. , 2018, CMAJ open.

[19]  C. Strube,et al.  Lyme borreliae prevalence and genospecies distribution in ticks removed from humans. , 2017, Ticks and tick-borne diseases.

[20]  J. P. Davis,et al.  Borrelia mayonii sp. nov., a member of the Borrelia burgdorferi sensu lato complex, detected in patients and ticks in the upper midwestern United States. , 2016, International journal of systematic and evolutionary microbiology.

[21]  R. Sykes,et al.  An estimate of Lyme borreliosis incidence in Western Europe† , 2016, Journal of public health.

[22]  R. Berner,et al.  Acrodermatitis Chronica Atrophicans. , 2016, The Journal of pediatrics.

[23]  P. Lantos,et al.  Chronic Lyme disease. , 2015, Infectious disease clinics of North America.

[24]  Randall S. Nelson,et al.  Update on Lyme Carditis, Groups at High Risk, and Frequency of Associated Sudden Cardiac Death — United States , 2014, Morbidity and Mortality Weekly Report.

[25]  H. Kilpatrick,et al.  The Relationship Between Deer Density, Tick Abundance, and Human Cases of Lyme Disease in a Residential Community , 2014, Journal of medical entomology.

[26]  F. Strle,et al.  Gender Disparity between Cutaneous and Non-Cutaneous Manifestations of Lyme Borreliosis , 2013, PloS one.

[27]  T. Mach,et al.  Lyme disease: review , 2012, Archives of medical science : AMS.

[28]  F. Strle,et al.  Lyme borreliosis , 2012, The Lancet.

[29]  R. Nadelman,et al.  Comparison of erythema migrans caused by Borrelia burgdorferi and Borrelia garinii. , 2011, Vector borne and zoonotic diseases.

[30]  M. Neteler,et al.  Lyme borreliosis in Europe. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[31]  I. Santino,et al.  Clinical and Serological Features of Patients with Suspected Lyme Borreliosis , 2011, International journal of immunopathology and pharmacology.

[32]  J. Hercogová,et al.  Identification of Anaplasma phagocytophilum and Borrelia burgdorferi sensu lato in patients with erythema migrans , 2009, Folia Microbiologica.

[33]  E. Skogvoll,et al.  Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial , 2008, The Lancet Neurology.

[34]  Sébastien Lê,et al.  FactoMineR: An R Package for Multivariate Analysis , 2008 .

[35]  H. Pfister,et al.  The Pathogenesis of Lyme Neuroborreliosis: From Infection to Inflammation , 2008, Molecular medicine.

[36]  M. Greenacre,et al.  Multiple Correspondence Analysis and Related Methods , 2006 .

[37]  A. Flahault,et al.  Lyme disease in France: a primary care-based prospective study , 2005, Epidemiology and Infection.

[38]  F. Strle,et al.  Intravenous ceftriaxone compared with oral doxycycline for the treatment of Lyme neuroborreliosis , 2005, Scandinavian journal of infectious diseases.

[39]  A. Papa,et al.  Borrelia valaisiana in Cerebrospinal Fluid , 2004, Emerging Infectious Diseases.

[40]  M. L. Vieira,et al.  First Isolation of Borrelia lusitaniae from a Human Patient , 2004, Journal of Clinical Microbiology.

[41]  F. Strle,et al.  Comparison of Erythema Migrans Caused by Borrelia afzelii and Borrelia garinii , 2004, Infection.

[42]  B. Schwartz,et al.  Occupational risk of Lyme disease: an epidemiological review , 2002, Occupational and environmental medicine.

[43]  S. O'connell,et al.  European Concerted Action on Lyme Borreliosis (EUCALB). , 1996 .

[44]  Jean Côté,et al.  Lyme Disease , 1991, International journal of dermatology.

[45]  M. Feld,et al.  Lyme carditis: an important cause of reversible heart block. , 1989, Annals of internal medicine.

[46]  A. Steere,et al.  The early clinical manifestations of Lyme disease. , 1983, Annals of internal medicine.

[47]  A. Steere,et al.  Lyme Carditis: Cardiac Abnormalities of Lyme Disease , 1980 .

[48]  A. Steere,et al.  Lyme borreliosis , 2016, Nature Reviews Disease Primers.

[49]  G Stanek,et al.  Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[50]  B. Florkin,et al.  [Borrelia-associated lymphocytoma cutis]. , 2010, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[51]  E. Diot,et al.  [Lyme borreliosis: census of adult patients hospitalized in Indre-et-Loire (France), from the Hospital Discharge Data (1999-2006)]. , 2010, Revue d'epidemiologie et de sante publique.

[52]  Elisabeth Catu L’Institut national de la santé et de la recherche médicale (INSERM) , 1989 .